WESTBOROUGH, Mass.– New data from Miach Orthopaedics’ ongoing Bridge Registry study continues to show promising results for the company’s BEAR® Implant, a device aimed at transforming treatment for anterior cruciate ligament (ACL) tears. The findings were presented during the 2025 annual meeting of the American Orthopaedic Society for Sports Medicine (AOSSM).
Researchers shared both one- and two-year outcomes from the real-world registry study, with the two-year data showing a 5% retear rate among the first 100 patients. That includes a 4% rate in patients aged 19 and older, and an 8% rate in patients 18 and under. Dr. Brian Lau and Dr. Jocelyn Wittstein of Duke University presented the findings at the conference. One-year outcomes, previously released, were also highlighted in poster format at the meeting.
Dr. Jacqueline Brady, an orthopedic surgeon at Oregon Health and Science University and co-principal investigator of the study, said the low failure rates support confidence in the BEAR Implant’s use in clinical settings. “It is important that we study this exciting new technology as we make adjustments for real-world use, such as stronger sutures and different fixation techniques to aid in direct visualization and restored anatomy of the repair,” she said. “I am honored to be part of this research.”
The Bridge Registry, launched in May 2023 under clinical trial number NCT05398341, tracks real-world use of the BEAR Implant with a focus on outcomes like knee function, measured by the IKDC Subjective Knee Evaluation at two years, and knee stability, measured by Lachman test scoring at one year. Along with Dr. Brady, the registry’s co-principal investigators include Dr. Sabrina Strickland of the Hospital for Special Surgery and Dr. Wittstein of Duke University.
Patrick McBrayer, president and CEO of Miach Orthopaedics, said the data reinforces confidence in the implant’s performance. “The positive outcomes demonstrated in the Bridge Registry support the continued safety and efficacy of the BEAR Implant, as evidenced by a low retear rate of 5%,” he said. “This and other registry data provide important insights into the real-world use of the BEAR Implant, accounting for variations in patient age, activity level and ACL tear type, as well as surgical technique.”
So far, 300 patients have been enrolled across a network of leading medical institutions including AdventHealth in Florida, Boston Children’s Hospital in Massachusetts, Duke University in North Carolina, Hospital for Special Surgery in New York, Oregon Health and Science University, Stanford University School of Medicine in California, Steamboat Orthopaedic & Spine Institute in Colorado, Auburn Community Hospital in New York, and Virtua Health in New Jersey.
